Jim Mazzo Joins Board of Directors at TearLab

Jim Mazzo Joins Board of Directors at TearLab

November 10, 2021

TearLab has announced the appointment of James V. Mazzo to the company’s Board of Directors.

According to TearLab, Mr. Mazzo's insights based on his industry experience and global reputation, will be important as TearLab strives to implement its growth strategy following recent restructuring.

Mr. Mazzo has more than 40 years of expertise in the medical device industry and is known for his ability to establish and operate world-class companies.

He previously served as CEO of Allergan's North American and European eye care organizations, as well as chairman, president, and CEO of Advanced Medical Optics (AMO), EVP of Abbott's global ophthalmology business, executive chair and CEO of AcuFocus, and global president of ophthalmic devices for Carl Zeiss Meditec.

Mr. Mazzo is currently the executive chairman of Neurotech, a retinal implant company, as well as an advisor to Avellino Labs, a biotechnology and genetic research firm. He also serves as a consultant for Zeiss and Bain Consulting.

He is the founder and chairman of OCTANe, a member of the International Intraocular Implant Club, and executive committee board member with the Medical Device Manufacturers Association.

"We are incredibly pleased and honored to bring an industry veteran like Jim to our Board of Directors as we prepare the organization for the expansion phase that lies ahead," said Executive Chairman of the Board and Accelmed General Partner Lior Shav.

"Accelmed remains committed to the success of TearLab and this addition only further strengthens what we believe is a well-positioned company, ready to deliver further growth while addressing the unmet needs in ocular surface disease. "

"I could not be more excited to join TearLab's Board of Directors," reported Mr. Mazzo. "At this time of growing global demand in eye care and diagnostics, the company's opportunities are many and the future is indeed very bright. I look forward to assisting leadership in their strategic decision-making."

Osmolarity testing enables clinicians to detect visually ocular surface disease, and is considered an essential test by the American Society of Cataract and Refractive Surgery

The precision of refractive measurements can be harmed by abnormal osmolarity. Clinicians can use the TearLab osmolarity test to correctly detect dry eye illness. It has a proven track record, with over 20 million tests completed in 50 countries around the world.